SuperX
  1. Home
  2. Stocks
  3. AGP
  4. News and notes

AGP · PHARMACEUTICALS

AGP news and notes AGP Limited

AGP Limited (AGP) news and notes: the SuperX note, what changed (5 items) and 1 news story. The note is written by SuperX’s AI from its own figures. What changed is listed newest first. Headlines are the publishers’ own words, linked to them.

What SuperX wrote about AGP

  1. AGP rose 0.44% on 20 Nov. The pharmaceuticals sector median was -0.0%, with 7 scrips up and 8 down.

  2. On 10 Nov AGP rose 3.9% on 0.6 times the usual volume. The sector rose the same way, with 14 of 15 names up.

  3. The annual period ends 31 Dec. Last year the company filed the same period's results on 24 Mar.

Written by SuperX’s analyst desk from SuperX’s own figures, from the close of 20 Nov 2026. Each number was checked against those figures. Not advice.

What changed for AGP, newest first

  • 20 Nov 2026Closed 151.65, +0.44%. Volume 62,324, 0.2 times the average of the 30 sessions before it, 266,515.
  • 20 Nov 2026Margin financing (MTS) open on AGP: 212,020 shares.
  • 16 Nov 2026Trend read changed to trending down: below the 50- and 200-day averages; down 14.8% over 3 months; within 3% of the 52-week low.
  • 30 Oct 2026Quarter ended 30 Sep 2026: earnings per share Rs 1.13, sales Rs 4.2 bn, down 52.9% on the same quarter a year before.
  • NextAnnual results (to 31 Dec 2026) expected 5 Feb 2027 – 29 Mar 2027, a projection. An estimate from the dates of the last 8 filings.

As of the close of 20 Nov 2026. Closes and notices: PSX. Margin financing: NCCPL. Trend read: SuperX, from daily closes. Volume: against the average of the 30 sessions before the last. Next results: an estimate from the dates of the last 8 filings. Not advice.

News about AGP

From 22 Oct 2026 to 22 Oct 2026. A story is listed here when its headline names the company and names three companies or fewer. Headlines are the publishers’ own words and link to them.

More on AGP

Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .